Highlights CALI BIOTPAR

Equities

CLDI

US3207031010

Market Closed - Nyse Other stock markets 21:10:00 15/07/2024 BST			5-day change	1st Jan Change
1.75 ^USD	+10.55%		+7.96%	-88.41%

07-08	Calidi Biotherapeutics, Inc. Enters into A Certain Loan Agreement with Dennis R. Conklin	CI
07-05	Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split	07-05	MT
Sector Update: Health Care Stocks Advance Late Afternoon	06-10	MT
Sector Update: Health Care	06-10	MT
Calidi Biotherapeutics Signs Virotherapy Deal With Siga Technologies -- Calidi Shares Surge Pre-Bell	06-10	MT
Calidi Biotherapeutics Collaborates with Siga Technologies to Advance Calidi?S Revolutionary Rtnova Virotherapy for Lung Cancer and Metastatic Solid Tumors	06-10	CI
Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting	06-03	CI
Calidi Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting	11-03	CI
Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director	24/10/23	CI
Calidi Biotherapeutics, Inc. executed a term sheet to acquire First Light Acquisition Group, Inc. from group of sellers in a reverse merger transaction.	11/09/23	CI
First Light Acquisition Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
First Light Acquisition Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
First Light Acquisition Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
First Light Acquisition to Take Calidi Biotherapeutics Public in SPAC Merger Deal	09/01/23	MT
Calidi Biotherapeutics, Inc. entered into an agreement and plan of merger to acquire First Light Acquisition Group, Inc. from group of sellers for approximately $440 million in a reverse merger transaction.	08/01/23	CI
First Light Acquisition Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
First Light Acquisition Group Shareholders Approve Merger Date Extension; Tom Vecchiolla Named Co-CEO	16/09/22	MT
First Light Acquisition Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/08/22	CI
First Light Acquisition Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	11/05/22	CI
First Light Acquisition Group, Inc. Reports Earnings Results for the Nine Months Ended December 31, 2021	31/03/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CALI BIOTPAR

Equities

CLDI

US3207031010

Highlights

Filters